Equities Analysts Set Expectations for IPSC FY2025 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities researchers at Chardan Capital issued their FY2025 earnings estimates for shares of Century Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst Y. Livshits forecasts that the company will post earnings per share of ($0.33) for the year. Chardan Capital has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Chardan Capital also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.64) EPS.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.02. The business had revenue of $4.18 million during the quarter, compared to analyst estimates of $0.67 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%.

A number of other equities analysts have also issued reports on IPSC. Guggenheim decreased their target price on shares of Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Piper Sandler decreased their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday, March 20th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a report on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $5.00.

Century Therapeutics Stock Performance

Shares of IPSC opened at $0.55 on Thursday. Century Therapeutics has a one year low of $0.52 and a one year high of $4.43. The stock’s fifty day moving average is $0.71 and its 200-day moving average is $1.13. The firm has a market capitalization of $47.19 million, a price-to-earnings ratio of -0.30 and a beta of 1.75.

Hedge Funds Weigh In On Century Therapeutics

Several large investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Century Therapeutics in the fourth quarter valued at $36,000. Jane Street Group LLC boosted its position in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP purchased a new position in Century Therapeutics in the 4th quarter worth about $52,000. Sei Investments Co. acquired a new stake in Century Therapeutics during the 4th quarter worth about $53,000. Finally, Two Sigma Investments LP purchased a new stake in Century Therapeutics during the fourth quarter valued at about $67,000. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.